Drugs create balancing act for patients with non-small cell lung cancer
News: Latest | Digests | Channels | Categories | Gallery
Posted on: December 14, 2020
Category: Medications
Drugs create balancing act for patients with non-small cell lung cancer
The results of a large, retrospective study of patients who received a form of immunotherapy for non-small cell lung cancer (NSCLC) revealed that patients may get more than one immune-related side effect, and identified a correlation between these multisystem immune-related adverse events (irAEs) and improved patient survival. In fact, patients who developed two irAEs did better, in terms of delaying the time to cancer progression and overall survival, than those who developed only one irAE. According to the researchers, this new information will be helpful in discussing with patients the spectrum of immune side effects that may occur from immunotherapy and the implications for their survival.
Welcome to the healthcare-only HIPAA - GDPR compliant cloud. Exclusively hosted on a HPC environment!
Learn more or start today by choosing your secure HIPAA - GDPR compliant server's Operating System bellow and pick the package that's best for you.
BIPmd makes it simple to launch in the cloud and scale up as you grow – whether you’re running one virtual machine, thousand or more.
Looking for a custom solution?
Our technicians can provide you with the best custom-made solutionss on the market, no matter whether you're a small business or large enterprise.
Get in touch